For research use only. Not for therapeutic Use.
BMS-192364 is targeting the Gα-RGS interaction to produce an inactive Gα-RGS complex. BMS-192364 reduces urinary bladder contraction and exert RGS-agonist properties by increasing the action of GAPs on Gq proteins. BMS-192364 inhibits calcium flux[1][2][3].
| Catalog Number | I003223 |
| CAS Number | 202822-21-7 |
| Synonyms | 2-(5-chloro-2-hydroxyphenyl)-5-[4-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-one |
| Molecular Formula | C15H9ClF3N3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C15H9ClF3N3O2/c16-10-5-6-12(23)11(7-10)22-14(24)20-13(21-22)8-1-3-9(4-2-8)15(17,18)19/h1-7,23H,(H,20,21,24) |
| InChIKey | XNRWPJIJOVVQRQ-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1C2=NN(C(=O)N2)C3=C(C=CC(=C3)Cl)O)C(F)(F)F |
| Reference | [1]. Kevin Fitzgerald, et al. Chemical genetics reveals an RGS/G-protein role in the action of a compound. PLoS Genet. 2006 Apr;2(4):e57. [2]. Maciej Salaga, et al. RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives. Bioessays. 2016 Apr;38(4):344-54. [3]. David P Basile, et al. A GAP in our knowledge of vascular signaling in acute kidney injury. Kidney Int. 2011 Aug;80(3):233-5. |
